Published 2025-01-01
“…Xiuyun Li,1 Bing Yu,2 Hui Li,3 Zhirui Liu,4 Xiaohan Fu,1 Ping Jiao,5 Lei Wang6 1Infection and Microbiology Research Laboratory for Women and Children, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, 250014, People’s Republic of China; 2Medical Affairs Department, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, 250014, People’s Republic of China; 3Pediatric Department, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, 250014, People’s Republic of China; 4Faculty of Medicine and Health, The University of Sydney, Camperdown NSW, 2050, Australia; 5Department of Pharmacy, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, 250012, People’s Republic of China; 6School of
Pharmaceutical Science @ Institute of Materia Medica. Shandong First Medical University @ Shandong Academy of Medical Sciences, Jinan, 250117, People’s Republic of ChinaCorrespondence: Ping Jiao; Lei Wang, Email jiaopingonlyone@163.com; wanglei1118@sdfmu.edu.cnBackground: Biofilm formation often represents significant challenges in managing of bloodstream infections associated with catheter use.Objective: Antimicrobial lock therapy serves as an adjunctive treatment for catheter-related infections, effectively eradicating or inhibiting biofilm growth.Methods: This review synthesizes the current knowledge on antifungal lock therapy (ALT) targeting clinically common fungi, primarily Candida species, based on both in vitro and in vivo studies (animals and patients) from the past decade.Results: Amphotericin B (AmB) and echinocandins are identified as the most promising antifungal agents for ALT. …”
Get full text
Article
